DongKoo Bio&Pharma Co. Ltd (006620) — Working Capital to Net Assets Ratio
DongKoo Bio&Pharma Co. Ltd (006620) has a Working Capital to Net Assets ratio of -8.1% as of September 2025. Working capital of ₩-9.01 Billion (current assets of ₩110.51 Billion minus current liabilities of ₩119.52 Billion) is measured against net assets of ₩110.66 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 006620 equity to assets ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
DongKoo Bio&Pharma Co. Ltd Working Capital to Net Assets (2015–2024)
This chart shows how DongKoo Bio&Pharma Co. Ltd's Working Capital to Net Assets ratio has evolved across 10 annual periods from 2015 to 2024. As of September 2025, the ratio stands at -8.1%, reflecting working capital of ₩-9.01 Billion against net assets of ₩110.66 Billion KRW. Check how tangible is DongKoo Bio&Pharma Co. Ltd's equity to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for DongKoo Bio&Pharma Co. Ltd (2015–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for DongKoo Bio&Pharma Co. Ltd from 2015 to 2024, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see how much is DongKoo Bio&Pharma Co. Ltd worth.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -7.6% | ₩-8.01 Billion | ₩105.33 Billion | ₩107.24 Billion | ₩115.25 Billion | ▼ -21.2 pp |
| 2023 | 13.6% | ₩15.05 Billion | ₩110.44 Billion | ₩88.36 Billion | ₩73.32 Billion | ▼ -7.3 pp |
| 2022 | 20.9% | ₩21.37 Billion | ₩102.11 Billion | ₩87.42 Billion | ₩66.04 Billion | ▼ -2.8 pp |
| 2021 | 23.8% | ₩23.81 Billion | ₩100.12 Billion | ₩73.83 Billion | ₩50.02 Billion | ▼ -9.9 pp |
| 2020 | 33.6% | ₩31.84 Billion | ₩94.65 Billion | ₩72.35 Billion | ₩40.51 Billion | ▼ -5.5 pp |
| 2019 | 39.2% | ₩33.56 Billion | ₩85.65 Billion | ₩71.90 Billion | ₩38.35 Billion | ▼ -2.7 pp |
| 2018 | 41.9% | ₩30.19 Billion | ₩72.10 Billion | ₩58.81 Billion | ₩28.62 Billion | ▲ +15.5 pp |
| 2017 | 26.3% | ₩9.94 Billion | ₩37.74 Billion | ₩44.52 Billion | ₩34.58 Billion | ▲ +57.9 pp |
| 2016 | -31.6% | ₩-6.97 Billion | ₩22.05 Billion | ₩32.18 Billion | ₩39.15 Billion | ▲ +671.0 pp |
| 2015 | -702.6% | ₩-17.92 Billion | ₩2.55 Billion | ₩24.85 Billion | ₩42.77 Billion | — |